文献速递皮肤肿瘤

BRAFV600变异等位基因频率预测转移性黑色素瘤患者接受BRAF和MEK抑制剂治疗的结局

BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-06-27

本研究纳入107例接受一线BRAF和MEK抑制剂治疗的BRAFV600突变转移性黑色素瘤患者,通过ROC曲线确定VAF截断值为41.3%。多因素分析显示,VAF>41.3%与更短的无进展生存期独立相关(HR 1.62),而总生存期缩短无统计学意义(HR 1.46,p=0.06)。BRAF基因扩增在训练队列和验证队列中分别占11%和7%。

要点

  • VAF截断值为41.3%,VAF>41.3%是无进展生存期的独立不良预后因素(HR 1.62)。
  • M1c/M1d分期和ECOG PS≥1也与更短的无进展生存期显著相关。
  • BRAF基因扩增在训练和验证队列中分别占11%和7%,与高VAF共存。

核心结论

  • 高VAF是接受BRAF和MEK抑制剂治疗的转移性黑色素瘤患者的独立不良预后因素。
  • 高VAF与BRAF扩增在7%-11%的患者中共存。

研究设计与样本

  • 研究纳入来自三个意大利黑色素瘤协作组中心的107例接受一线BRAF和MEK抑制剂治疗的转移性黑色素瘤患者。
  • VAF通过下一代测序在治疗前基线组织样本中测定。
  • BRAF拷贝数变异与VAF的相关性在辅助研究中通过训练队列和验证队列的黑色素瘤组织样本及细胞系进行分析。

主要发现

  • ROC曲线确定的VAF截断值为41.3%。
  • 多因素分析中,M1c/M1d患者无进展生存期显著更短(HR 2.25,95%CI 1.41-3.6,p<0.01)。
  • VAF>41.3%的患者无进展生存期显著更短(HR 1.62,95%CI 1.04-2.54,p<0.05)。
  • ECOG PS≥1的患者无进展生存期显著更短(HR 1.82,95%CI 1.15-2.88,p<0.05)。
  • M1c/M1d患者总生存期显著更短(HR 2.01,95%CI 1.25-3.25,p<0.01);VAF>41.3%患者总生存期缩短(HR 1.46,95%CI 0.93-2.29,p=0.06),ECOG PS≥1患者总生存期缩短(HR 1.52,95%CI 0.94-2.87,p=0.14)。

关键数值与推荐

  • VAF截断值为41.3%(通过ROC曲线确定)。
  • BRAF基因扩增在训练队列中占11%,在验证队列中占7%。

临床怎么用

  • 在转移性黑色素瘤患者接受BRAF和MEK抑制剂治疗前,可检测BRAFV600 VAF,VAF>41.3%提示无进展生存期较短。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prognostic impact of variant allele frequency (VAF) on clinical outcome in BRAFV600 mutated metastatic melanoma patients (MMPs) receiving BRAF (BRAFi) and MEK inhibitors (MEKi) is unclear. MATERIALS AND METHODS: A cohort of MMPs receiving first line BRAFi and MEKi was identified by inspecting dedicated databases of three Italian Melanoma Intergroup centres. VAF was determined by next generation sequencing in pre-treatment baseline tissue samples. Correlation between VAF and BRAF copy number variation was analysed in an ancillary study by using a training and a validation cohort of melanoma tissue samples and cell lines. RESULTS: Overall, 107 MMPs were included in the study. The VAF cut-off determined by ROC curve was 41.3%. At multivariate analysis, progression-free survival (PFS) was significantly shorter in patients with M1c/M1d [HR 2.25 (95% CI 1.41-3.6, p < 0.01)], in those with VAF >41.3% [HR 1.62 (95% CI 1.04-2.54, p < 0.05)] and in those with ECOG PS ≥1 [HR 1.82 (95% CI 1.15-2.88, p < 0.05)]. Overall survival (OS) was significantly shorter in patients with M1c/M1d [HR 2.01 (95% CI 1.25-3.25, p < 0.01)]. Furthermore, OS was shorter in patients with VAF >41.3% [HR 1.46 (95% CI 0.93-2.29, p = 0.06)] and in patients with ECOG PS ≥1 [HR 1.52 (95% CI 0.94-2.87, p = 0.14)]. BRAF gene amplification was found in 11% and 7% of samples in the training and validation cohort, respectively. CONCLUSIONS: High VAF is an independent poor prognostic factor in MMP receiving BRAFi and MEKi. High VAF and BRAF amplification coexist in 7%-11% of patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Mandalà M, Palmieri G, Ludovini V, et al. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors. J Eur Acad Dermatol Venereol. 2023. PMID: 37335879. doi:10.1111/jdv.19281

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。